UniPharma Co., Ltd. (TPEX:6621)

Market Cap	426.01M -14.3%
Revenue (ttm)	90.79M -8.8%
Net Income	-38.84M
EPS	-1.09
Shares Out	35.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	344,842
Average Volume	164,716
Open	12.30
Previous Close	12.30
Day's Range	11.90 - 12.30
52-Week Range	11.40 - 18.10
Beta	-0.07
RSI	37.45
Earnings Date	May 20, 2026

About UniPharma

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves m...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 31
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6621

Financial Performance

In 2024, UniPharma's revenue was 93.46 million, a decrease of -9.46% compared to the previous year's 103.22 million. Losses were -24.82 million, 13.8% more than in 2023.